MacroGenics Croissance future
Future contrôle des critères 1/6
Les bénéfices de MacroGenics devraient diminuer de 6.2% par an tandis que son chiffre d'affaires annuel devrait croître de 12.4% par an. Le BPA devrait croître de en baisse de 1.3% par an.
Informations clés
-6.2%
Taux de croissance des bénéfices
-1.28%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 25.4% |
| Taux de croissance des recettes | 12.4% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Good |
| Dernière mise à jour | 07 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour de l'analyse • Apr 26
MGNX: Antibody Drug Conjugate Pipeline And 2026 Data Will Drive Repricing
Narrative Update on MacroGenics Analysts have raised their price targets on MacroGenics by $2 to $4. They cite updated revenue assumptions and interest in the company’s antibody drug conjugate pipeline as key factors behind the change.Mise à jour de l'analyse • Apr 12
MGNX: Antibody Drug Conjugate Pipeline And Tubulus Deal Will Drive Repricing
Analysts raised their price target for MacroGenics from $5.00 to $9.00, citing updated assumptions for potential revenue growth, slightly higher profit margins, a lower discount rate and recent positive sentiment following the Tubulus deal and the outlook for antibody-drug conjugate data. Analyst Commentary Bullish analysts are pointing to recent research updates as a sign that expectations for MacroGenics are shifting toward a more constructive view, with price targets and ratings adjusted to reflect changing assumptions around future execution and potential revenue streams.Seeking Alpha • Apr 10
MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble
Summary MacroGenics (MGNX) is rated Hold, reflecting significant upside potential but high risk and a limited funding runway beyond 2027. MGNX’s pipeline includes antibody drug conjugates and lorigerlimab, with the latter’s Phase 2 clinical hold recently lifted by the FDA. Key 2026 catalysts include clinical data from MGC026, MGC028, and the LINNET study, plus an IND submission for MGC030. Despite past setbacks and a $190m cash position, MGNX’s current valuation implies little pipeline value, making study success critical for future funding. Read the full article on Seeking AlphaArticle d'analyse • Jan 06
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...
Mise à jour de l'analyse • Sep 25
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
The consensus analyst price target for MacroGenics increased to $3.75, primarily reflecting a higher expected future P/E multiple despite a decline in net profit margin. What's in the News Eric Risser appointed Chief Executive Officer, succeeding long-time CEO Scott Koenig; Risser has extensive company and industry experience, having led corporate development efforts that generated $1.6 billion in non-dilutive capital.Article d'analyse • Sep 08
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 30% But Its Business Prospects Need A Lift Too
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders would be excited to see that the share price has had a great month...Mise à jour de l'analyse • Aug 16
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Despite an improving net profit margin and a sharply lower future P/E multiple reflecting more attractive valuation, the consensus analyst price target for MacroGenics has been notably reduced from $4.20 to $3.40. What's in the News Eric Risser appointed CEO, succeeding longtime leader Scott Koenig; Risser brings significant operational and business development experience, including generating over $1.6 billion in non-dilutive capital for the company.Article d'analyse • Jul 24
MacroGenics, Inc. (NASDAQ:MGNX) Surges 37% Yet Its Low P/S Is No Reason For Excitement
MacroGenics, Inc. ( NASDAQ:MGNX ) shares have had a really impressive month, gaining 37% after a shaky period...Article d'analyse • May 21
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders will have a reason to smile today, with the analysts making substantial...Article d'analyse • Apr 14
MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the MacroGenics, Inc. ( NASDAQ:MGNX ) share price has dived 42% in the last thirty...
Nouvelle analyse • Apr 02
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Future revenue growth potential hinges on successful trial outcomes and product approvals in ongoing and upcoming clinical studies.Article d'analyse • Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Unfortunately for some shareholders, the MacroGenics, Inc. ( NASDAQ:MGNX ) share price has dived 26% in the last thirty...Seeking Alpha • Feb 27
MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far
Summary MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. MGNX holds $179.6M in cash and equivalents, with a sustainable cash burn rate for up to 5 years. Sale of the margetuximab franchise poises the company for further financial stability. Operating expenses are expected to rise as clinical programs advance, with management projecting a cash runway into 2026. I think this is a conservative estimate. Although a lot has changed, I think these price levels are attractive for a tentative investment based on catalysts I anticipate in 2025 and beyond. Read the full article on Seeking AlphaSeeking Alpha • Dec 05
MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy
Summary MacroGenix was previously rated as a "Hold" due to uncertain revenue streams and high annual expenses of ~$300 million. Since the initial rating, MacroGenix's stock has dropped approximately 33%, reflecting ongoing financial challenges. The company's reliance on episodic milestones and minimal product revenues makes it unattractive for new investors. Existing investors might accept the risk, but the current financial outlook remains unattractive for prospective buyers. Read the full article on Seeking AlphaArticle d'analyse • Aug 01
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders will have a reason to smile today, with the analysts making substantial...Article d'analyse • Jul 30
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...Article d'analyse • Jul 12
We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Article d'analyse • May 13
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders that were waiting for something to happen have been dealt a blow with a...Seeking Alpha • May 13
MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
Summary Macrogenics' stock valuation has dropped over 70% after its first quarter update, creating a new opportunity for investors. The spotlight is on their product vobramitamab duocarmazine, and the phase 2 TAMARACK trial. Macrogenics has between 4 and 5 quarters of cash and investments on hand. Read the full article on Seeking AlphaSeeking Alpha • Apr 05
MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Summary Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024. Radiographic progression-free survival data from the phase 2 TAMARACK study, expected by fall of 2024. The global prostate cancer market size is estimated to reach $27.51 billion by 2032. Read the full article on Seeking AlphaArticle d'analyse • Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, MacroGenics, Inc. ( NASDAQ:MGNX ) shares have been powering on, with a gain of 27% in...Seeking Alpha • Feb 15
MacroGenics: Trying To Build A Better Everything
Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and risks in their drug development and commercialization efforts. Read the full article on Seeking AlphaArticle d'analyse • Jan 09
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
With a price-to-sales (or "P/S") ratio of 5.4x MacroGenics, Inc. ( NASDAQ:MGNX ) may be sending very bullish signals at...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 148 | -168 | -167 | N/A | 3 |
| 12/31/2027 | 99 | -149 | -146 | N/A | 4 |
| 12/31/2026 | 106 | -86 | -135 | N/A | 6 |
| 12/31/2025 | 150 | -75 | -83 | -81 | N/A |
| 9/30/2025 | 128 | -76 | -165 | -162 | N/A |
| 6/30/2025 | 165 | -36 | -75 | -72 | N/A |
| 3/31/2025 | 154 | -56 | -72 | -70 | N/A |
| 12/31/2024 | 150 | -67 | -72 | -68 | N/A |
| 9/30/2024 | 141 | -98 | -62 | -58 | N/A |
| 6/30/2024 | 41 | -136 | -157 | -153 | N/A |
| 3/31/2024 | 43 | -23 | -114 | -111 | N/A |
| 12/31/2023 | 59 | -9 | -80 | -78 | N/A |
| 9/30/2023 | 121 | 50 | -22 | -21 | N/A |
| 6/30/2023 | 152 | 7 | 3 | 5 | N/A |
| 3/31/2023 | 165 | -91 | -45 | -42 | N/A |
| 12/31/2022 | 152 | -120 | -91 | -87 | N/A |
| 9/30/2022 | 93 | -191 | -175 | -171 | N/A |
| 6/30/2022 | 67 | -219 | -182 | -176 | N/A |
| 3/31/2022 | 72 | -217 | -179 | -172 | N/A |
| 12/31/2021 | 77 | -202 | -150 | -144 | N/A |
| 9/30/2021 | 116 | -146 | -103 | -95 | N/A |
| 6/30/2021 | 119 | -129 | -113 | -106 | N/A |
| 3/31/2021 | 108 | -136 | -102 | -97 | N/A |
| 12/31/2020 | 105 | -130 | -118 | -112 | N/A |
| 9/30/2020 | 77 | -158 | -148 | -144 | N/A |
| 6/30/2020 | 78 | -167 | -140 | -136 | N/A |
| 3/31/2020 | 68 | -152 | -152 | -148 | N/A |
| 12/31/2019 | 64 | -152 | -139 | -134 | N/A |
| 9/30/2019 | 55 | -166 | N/A | -123 | N/A |
| 6/30/2019 | 57 | -155 | N/A | -143 | N/A |
| 3/31/2019 | 65 | -167 | N/A | -152 | N/A |
| 12/31/2018 | 60 | -171 | N/A | -153 | N/A |
| 9/30/2018 | 197 | -21 | N/A | -14 | N/A |
| 6/30/2018 | 178 | -34 | N/A | -9 | N/A |
| 3/31/2018 | 160 | -32 | N/A | 18 | N/A |
| 12/31/2017 | 158 | -20 | N/A | 14 | N/A |
| 9/30/2017 | 10 | -160 | N/A | -126 | N/A |
| 6/30/2017 | 12 | -147 | N/A | -45 | N/A |
| 3/31/2017 | 91 | -66 | N/A | -47 | N/A |
| 12/31/2016 | 92 | -59 | N/A | -44 | N/A |
| 9/30/2016 | 95 | -52 | N/A | -40 | N/A |
| 6/30/2016 | 106 | -34 | N/A | -97 | N/A |
| 3/31/2016 | 32 | -96 | N/A | -89 | N/A |
| 12/31/2015 | 101 | -20 | N/A | -14 | N/A |
| 9/30/2015 | 98 | -11 | N/A | -10 | N/A |
| 6/30/2015 | 102 | 1 | N/A | -16 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: MGNX devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: MGNX devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: MGNX devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de MGNX ( 12.4% par an) devrait croître plus rapidement que le marché US ( 11.6% par an).
Croissance élevée des revenus: Le chiffre d'affaires de MGNX ( 12.4% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de MGNX devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/11 13:21 |
| Cours de l'action en fin de journée | 2026/05/11 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
MacroGenics, Inc. est couverte par 17 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Etzer Darout | Barclays |
| Peter Lawson | Barclays |
| Stephen V. Byrne | BofA Global Research |